Skip to main content

Jubilant Biosys licenses its Kinase ChemBioBase to Astex Technology

NEW YORK, July 8 - Jubilant Biosys of Bangalore, India said today that it has licensed its kinase target database to Astex Technology, of Cambridge, UK.

 

Under the license, Astex will be able to use the database, called the Kinase ChemBioBase, in its structure-based research on lead compounds for drug discovery.

 

The content in this database is what gives Jubilant a competitive edge, according to Sreeni Devidas, vice president of business development and strategy at Jubilant. The database "has all the relevant information that has never been worked on in kinases," he said, including "over 170,000 compounds and 200,000 structure-activity relationships."

 

Jubilant provides bioinformatics and chemoinformatics services.

 

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.